Imbalanced matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 activities in patients with thromboangiitis obliterans


Autoria(s): Dellalibera-Joviliano, Renata; Jacob-Ferreira, Anna L. B.; Joviliano, Edwaldo Edner; Tanus-Santos, Jose E.; Evora, Paulo R. B.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

05/11/2013

05/11/2013

2012

Resumo

The pathogenic mechanisms of thromboangiitis obliterans (TAO) are not entirely known and the imbalance of matrix metalloproteinases (MMPs) plays a role in vascular diseases. We evaluated the MMP-2 and MMP-9 circulating levels and their endogenous tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in TAO patients with clinical manifestations. The study included 20 TAO patients (n = 10 female, n = 10 male) aged 38-59 years under clinical follow-up. The patients were classified into two groups: (1) TAO former smokers (n = 11) and (2) TAO active smokers (n = 9); the control group included normal volunteer non-smokers (n = 10) and active smokers without peripheral artery disease (n = 10). Patient plasma samples were used to analyze MMP-2 and MMP-9 levels using zymography, and TIMP-1 and TIMP-2 concentrations were determined by enzyme-linked immunosorbent assays. The analysis of MMP-2/TIMP-2 and MMP-9/TIMP-1 ratios (which were used as indices of net MMP-2 and MMP-9 activity, respectively) showed significantly higher MMP-9/TIMP-1 ratios in TAO patients (p < 0.05). We found no significant differences in MMP-2/TIMP-2 ratios (p > 0.05). We found higher MMP-9 levels and decreased levels of TIMP-1 in the TAO groups (active smokers and former smokers), especially in active smokers compared with the other groups (all p < 0.05). MMP-2 and TIMP-2 were not significantly different in patients with TAO as compared to the control group (p > 0.05). In conclusion, our results showed increased MMP-9 and reduced TIMP-1 activity in TAO patients, especially in active smokers compared with non-TAO patients. These data suggest that smoke compounds could activate MMP-9 production or inhibit TIMP-1 activity.

FAEPA (HCFMRP/USP)

FAEPA (HCFMRP/USP)

FAPESP

FAPESP

Identificador

VASCULAR MEDICINE, LONDON, v. 17, n. 2, supl. 2, Part 3, pp. 73-78, APR, 2012

1358-863X

http://www.producao.usp.br/handle/BDPI/41549

10.1177/1358863X11435979

http://dx.doi.org/10.1177/1358863X11435979

Idioma(s)

eng

Publicador

SAGE PUBLICATIONS LTD

LONDON

Relação

VASCULAR MEDICINE

Direitos

closedAccess

Copyright SAGE PUBLICATIONS LTD

Palavras-Chave #MATRIX METALLOPROTEINASES #THROMBOANGIITIS OBLITERANS #TISSUE INHIBITORS OF METALLOPROTEINASE #VASCULAR INJURY #CARDIOVASCULAR RISK-FACTORS #BUERGERS-DISEASE #MATRIX METALLOPROTEINASES #PLASMA MATRIX-METALLOPROTEINASE-9 #MMP-9 ACTIVITIES #HEART #HYPERTENSION #MYOCARDIUM #(MMP)-2 #MARKERS #PERIPHERAL VASCULAR DISEASE
Tipo

article

original article

publishedVersion